anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ensure that the injection is given immediately after preparation of the dose.

The intravitreal injection procedure must be carried out under aseptic conditions, which includes the use of surgical hand disinfection, sterile gloves, a sterile drape and a sterile eyelid speculum (or equivalent), and the availability of sterile paracentesis equipment (if required). Adequate anesthesia and a broad-spectrum topical microbicide to disinfect the periocular skin, eyelid, and ocular surface should be administered prior to the injection.

Inject slowly until the rubber stopper reaches the end of the syringe to deliver the volume of 0.05 mL. Confirm delivery of the full dose by checking that the rubber stopper has reached the end of the syringe barrel.

Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure (IOP). Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, a sterile paracentesis needle should be available.

Following intravitreal injection, patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment (e.g., eye pain, redness of the eye, photophobia, blurring of vision) without delay [see Patient Counseling Information (17)].

Each vial or pre-filled syringe should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial or pre-filled syringe should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before BEOVU is administered to the other eye.

Any unused medicinal product or waste material should be disposed of in accordance with local regulations.
The Intervention group receives the SYNC intervention in addition to typical child welfare services (i.e., services as usual). The SYNC intervention includes 10 weekly remote (videoconference) 90-minute sessions delivered by a facilitator and a near-peer young adult aged 20-26, both with lived experience in child welfare.
An automated system for management of information and distribution of materials associated with sterilization procedures includes a network server (14) and client computers that communicate via a computer network (12). The client computers are distributed among sterilization facilities (16A-16C) that require sterilization services. The network server (14) exchanges a variety of information with the sterilization facilities (16A-16C). In response to information from client computers, the network server (14) may trigger distribution of materials to sterilization facilities (16A-16C), and generates reports for record-keeping or cost-accounting purposes. The information distributed by the network server (14) may pertain to the operation, maintenance and control of sterilization equipment, characteristics and capabilities of sterilization materials, and expert technical advice. The information received from sterilization facilities (16A-16C) includes requests for information, orders for purchase and delivery of materials, and sterilization process information documenting sterilization procedures performed within a sterilization facility.
The invention discloses an application of multinoside in preparing a medicament for treating inflammatory bowel disease. The invention adopts 5% DSS to construct a mouse colitis model to evaluate the treatment effect of the multinoside on IBD, and provides the application of the multinoside in preparing medicines for treating inflammatory bowel diseases. The multinoside is found to be capable of treating colitis and has the drug effect which is not weaker than that of the positive control drug mesalazine. The invention also provides a method for treating colitis by using rosapone, which achieves the aim of treatment by inducing the level of DNA repair enzyme TRAX to rise. Through a SILAC proteomics method, the combination with mass spectrometry shows that the multiflorose glycoside can significantly up-regulate the expression of TRAX protein, and the TRAX plays a very critical role in DNA damage repair and can help to maintain the integrity of genome. Furthermore, the multinoside can play a role in treating inflammatory bowel diseases through TRAX protein, and repair intestinal injury.
BACKGROUND: Walnut anthracnose caused by Colletotrichum gloeosporioides seriously endangers the yield and quality of walnut, and has now become a catastrophic disease in the walnut industry. Therefore, understanding both pathogen invasion mechanisms and host response processes is crucial to defense against C. gloeosporioides infection.
RESULTS: Here, we investigated the mechanisms of interaction between walnut fruits (anthracnose-resistant F26 fruit bracts and anthracnose-susceptible F423 fruit bracts) and C. gloeosporioides at three infection time points (24hpi, 48hpi, and 72hpi) using a high-resolution time series dual transcriptomic analysis, characterizing the arms race between walnut and C. gloeosporioides. A total of 20,780 and 6670 differentially expressed genes (DEGs) were identified in walnut and C. gloeosporioides against 24hpi, respectively. Generous DEGs in walnut exhibited opposite expression patterns between F26 and F423, which indicated that different resistant materials exhibited different transcriptional responses to C. gloeosporioides during the infection process. KEGG functional enrichment analysis indicated that F26 displayed a broader response to C. gloeosporioides than F423. Meanwhile, the functional analysis of the C. gloeosporioides transcriptome was conducted and found that PHI, SignalP, CAZy, TCDB genes, the Fungal Zn (2)-Cys (6) binuclear cluster domain (PF00172.19) and the Cytochrome P450 (PF00067.23) were largely prominent in F26 fruit. These results suggested that C. gloeosporioides secreted some type of effector proteins in walnut fruit and appeared a different behavior based on the developmental stage of the walnut.
CONCLUSIONS: Our present results shed light on the arms race process by which C. gloeosporioides attacked host and walnut against pathogen infection, laying the foundation for the green prevention of walnut anthracnose.
The standard breathing and attention training (BAT) includes guided instructions on deep breathing and relaxation. Participants will practice standard BAT once a day for 15 minutes for 5 days in a row.
Cuproptosis-related key genes play a significant role in the pathological processes of acute myocardial infarction (AMI). However, a complete understanding of the molecular mechanisms behind this participation remains elusive. This study was designed to identify genes and immune cells critical to AMI pathogenesis. Based on the GSE48060 dataset (31 AMI patients and 21 healthy persons, GPL570-55999), we identified genes associated with dysregulated cuproptosis and the activation of immune responses between normal subjects and patients with a first myocardial attack. Two molecular clusters associated with cuproptosis were defined in patients with AMI. Immune infiltration analysis showed that there was significant immunity heterogeneity among different clusters. Multiple immune responses were closely associated with Cluster2-specific differentially expressed genes (DEGs). The generalized linear model machine model presented the best discriminative performance with relatively lower residual and root mean square error, and a higher area under the curve (AUC = 0.870). A final two-gene-based generalized linear model was constructed, exhibiting satisfactory performance in two external validation datasets (AUC = 0.719, GSE66360 and AUC = 0.856, GSE123342). Column graph, calibration curve, and decision curve analyses also proved the accuracy of AMI prediction. We also constructed a mouse C57BL/6 model of AMI (3 h, 48 h, and 1 week) and used qRT-PCR and immunofluorescence to detect the expression changes of CBLB and ZNF302. In this study, we present a systematic analysis of the complex relationship between cuproptosis and a first AMI attack, and provide new insights into the diagnosis and treatment of AMI.
Prior to participating in the study patients complete an online baseline questionnaire to assess anxiety and depression and general quality of life, as well as some specific questions related to their coping. They are also interviewed by a clinician who rates their level of anxiety and depression. After this, patients use the BNT001 app and undergo 10 sessions of CBSM over 45-60 minutes each consisting of cancer-specific educational videos, guided relaxation training, interactive exercises, and discussion modules. Following completion of the 5th session, patients undergo a telephone check-in assessment to see how things are going, update their treatments and medications, and schedule a phone call to assess for adverse events. At the end of the 10th session, patients complete a post-treatment online questionnaire and a phone debriefing interview to discuss their experience with the intervention.
OBJECTIVE: To compare the costotransversectomy (CTV) and transpedicular (TP) approaches versus the transfacet (TF) approach for the surgical treatment of calcific thoracic spine herniations (cTDH), in terms of surgical and clinical outcomes.
BACKGROUND: Surgical approaches for cTDH are debated. Anterior approaches are recommended, while posterolateral approaches are preferred for non-calcific, paramedian, and lateral hernias. Currently, there is limited evidence about the superiority of a more invasive surgical approach, such as CTV or TP, over TF, a relatively less invasive approach, in terms of neurological outcome, pain, and surgical complications, for the treatment of cTDH.
METHODS: A retrospective, observational, monocentric study was conducted on patients who underwent posterolateral thoracic approaches for symptomatic cTDH, between 2010 and 2023, at our institute. Three groups were drafted, based on the surgical approach used: TF, TP, and CTV. All procedures were assisted by intraoperative CT scan, spinal neuronavigation, and intraoperative neuromonitoring. Analyzed factors include duration of surgery, amount of bone removal, intraoperative blood loss, CSF leak, need of instrumentation for iatrogenic instability, degree of disc herniation removal, myelopathy recovery. Afterwards, a statistical analysis was performed to investigate the bony resection of the superior posterior edge of the vertebral soma. The primary outcome was the partial or total herniation removal.
RESULTS: This study consecutively enrolled 65 patients who underwent posterolateral thoracic surgery for cTDH. The TF approach taking the least, and the CTV the longest time (p < 0.01). No statistical difference was observed between the three mentioned approaches, in terms of intraoperative blood loss, dural leakage, post-resection instrumentation, total herniation removal, or myelopathy recovery. An additional somatic bony resection was successful in achieving total herniation removal (p < 0.01), and the extent of bony resection was directly proportional to the extent of hernia removal (p < 0.01).
CONCLUSIONS: No statistically significant differences were highlighted between the TP, TF, and CTV regarding the extent of cTDH removal, the postoperative complications, and the neurological improvement. The described somatic bone resection achieved significant total herniation removal and was directly proportional to the preop against postop anteroposterior diameter difference.
ZEN003694 will be administered PO QD with Talazoparib PO QD at the RP2D in 28-day cycles. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2. Includes sites in the US and EU.
In the adjuvant treatment trial [see Clinical Studies (14.1)], 400 patients who received Oxaliplatin with fluorouracil/leucovorin were greater than or equal to 65 years. The effect of Oxaliplatin in patients greater than or equal to 65 years was not conclusive. Patients greater than or equal to 65 years receiving Oxaliplatin experienced more diarrhea and grade 3-4 neutropenia (45% vs 39%) compared to patients less than 65 years. 

In the previously untreated advanced colorectal cancer trial [see Clinical Studies (14.2)], 99 patients who received Oxaliplatin with fluorouracil and leucovorin were greater than or equal to 65 years. The same efficacy improvements in response rate, time to tumor progression, and overall survival were observed in the greater than or equal to 65 years patients as in the overall study population. Adverse reactions were similar in patients less than 65 and greater than or equal to 65 years, but older patients may have been more susceptible to diarrhea, dehydration, hypokalemia, leukopenia, fatigue, and syncope. 

In the previously treated advanced colorectal cancer trial [see Clinical Studies (14.3)], 55 patients who received Oxaliplatin with fluorouracil and leucovorin were greater than or equal to 65 years. No overall differences in effectiveness were observed between these patients and younger adults. Adverse reactions were similar in patients less than 65 and greater than or equal to 65 years, but older patients may have been more susceptible to diarrhea, dehydration, hypokalemia, and fatigue. 

No significant effect of age on the clearance of ultrafiltrable platinum has been observed [see Clinical Pharmacology (12.3)].
The present invention provides anti-tumor peptides of formula I, A-B-NR3-CHD-CH(OCH3)-CH2CO-E-K, and the acid salts thereof. A is an amino acid residue selected from the group consisting of N-methyl-D-prolyl, N-methyl-D-homoprolyl and N,N-dimethyl-2-ethylphenylglycyl, or an amino acid residue, of the formula R1R2N-CHX-CO, wherein R1 is a methyl group or an ethyl group, R2 is a hydrogen atom, a methyl group or an ethyl group, and X is an alkyl group. B is an amino acid residue selected from the group consisting of valyl, isoleucyl, leucyl, and 2-t-butylglycyl. R3 is a hydrogen atom or a methyl group. D is a normal or branched C2-C5-alkyl group. E is an amino acid residue selected from the group consisting of prolyl, homoprolyl, 5-methylprolyl, and phenylalanyl, or E is a residue derived from an amino acid comprising a pyrrolidine group. K is an alkoxy group or an amino group. An additional embodiment of the present invention is a method for treating a malignancy in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound or compounds of formula I in a pharmaceutically acceptable composition.
FIELD: medicine. SUBSTANCE: this method prescribes sampling cerebrospinal fluid batchwise (5 to 10 ml) in total amount of 2 to 3 ml per 1 kg of patient's mass, purifying sampled cerebrospinal fluid using activated fibrous material having total benzol pore volume of more than 0.29 cu. cm/g, ratio between volume of micropores and transient pores ranging from 1.3 to 2.3 units, and finally reinjecting purified fluid into cerebrospinal canal. Disclosed method further prescribes using purpose-designed syringe characterized by specific constructional traits that allow expanding its functional capabilities. Syringe incorporates two interconnected bodies, rods and pistons. Subpiston space of first body houses adsorption member compressed by piston. Piston and rod housed in first body have through opening via which subpiston space of first body communicates with subpiston space of second one. Amount of cerebrospinal fluid can be checked by referring to scale marked on second body. EFFECT: disclosed method permits enhancing effectiveness of traditional methods of intensive medicamentous therapy; lower rate of fatal outcomes. 2 cl, 2 dwg, 4 tbl
Selective catheterization of segmental or more peripheral arteries in the procedure of transarterial treatment could be crucial in making a significant difference in survival outcome (1). Subsegmental chemoembolization (TACE) leading to portal vein visualization is associated with a higher chance of complete response (2), and complete response is a robust predictor of better overall survival (3). Selective TACE might also help to preserve liver function because TACE damages liver parenchyma and repeated TACE could lead to deterioration in liver function (4). In a procedure of ultra-selective TACE, each of the arterial tumor feeders is supposed to be catheterized for complete treatment of the whole tumor when there are multiple tumor feeders (5), it could be time consuming and technically challenging to achieve catheterize all the tumor feeders at a sub-subsegmental level when difficult arterial anatomy is encountered, even with the guidance of a automated tumor-feeders detection software (6). In the angioarchitecture of HCC, arterial tumor feeders lead to tumor sinusoid which is an interconnected network of vascular channel within the tumor substance (7). It is postulated that all arterial tumor feeders supplying a HCC tumor are interconnected with each other through the tumor sinusoid, such that when one of the feeders is catheterized for delivery of a liquid embolic agent, the whole tumor sinusoid will be embolized, if the arterial blood flow in all the other feeders are stopped temporarily to create a negative pressure gradient.
The invention relates to a peroral liquid of traditional Chinese medicine used for promoting fowl growth. The peroral liquid comprises the components in parts by weight as follows: 15-30 parts of rice sprouts, 5-15 parts of scorched arecas, 10-20 parts of green husks, 10-20 parts of fructus aurantii immaturus, 20-40 parts of antifebrile dichroa, and 5-10 parts of fructus amomi. The invention provides the efficient and stable peroral liquid extracted from natural herbs, and the peroral liquid has the function of promoting digestion, and achieves the effect of treating both symptoms and causes, as well as the intended purpose of growth promotion. At the same time, the medicine provided by the invention is the peroral liquid, which can be quickly dispersed in feeding drinking water. Fowls are supplied with medicine by drinking water, thereby promoting absorption. In addition, the medicine has the advantages of safe usage, no toxic or side effect, simple and feasible process, and remarkable treatment effect.
Chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma have posed a significant healthcare and economic cost over a prolonged duration worldwide. At present, available treatments are limited to a range of preventive medicines, such as mono- or multiple-drug therapy, which necessitates daily use and are not considered as viable treatments to reverse the inflammatory processes of airway remodelling which is inclusive of the alteration of intra and extracellular matrix of the airway tract, death of epithelial cells, the increase in smooth muscle cell and the activation of fibroblasts. Hence, with the problem in mind a considerable body of study has been dedicated to comprehending the underlying factors that contribute to inflammation within the framework of these disorders. Hence, adequate literature that has unveiled the necessary cellular probing to reduce inflammation in the respiratory tract by improving the selectivity and precision of a novel treatment. However, through cellular probing cellular mechanisms such as the downregulation of various markers, interleukin 8, (IL-8), Interleukin 6 (IL-6), interleukin 1β (IL-1β) and tumor necrosis factor-α (TNF-α) have been uncovered. Hence, to target such cellular probes implementation of phytoceuticals encapsulated in an advanced drug delivery system has shown potential to be a solution with in vitro and in vivo studies highlighting their anti-inflammatory and antioxidant effects. However, the high costs associated with advanced drug delivery systems and the limited literature focused exclusively on nanoparticles pose significant challenges. Additionally, the biochemical characteristics of phytoceuticals due to poor solubility, limited bioavailability, and difficulties in mass production makes it difficult to implement this product as a treatment for COPD and asthma. This study aims to examine the integration of many critical features in the context of their application for the treatment of chronic inflammation in respiratory disorders.
The objective of this study was to investigate how supplementing vitamin C (VC) in milk affects growth, starter intake, blood metabolites, and the health of young calves classified into healthy or diarrheic groups. Calves were classified as diarrheic if they experienced diarrhea for at least 3 days from birth to day 7, otherwise, they were classified as healthy (i.e., days with diarrhea < 3). From day 8 of age, a total of 48 Holstein calves were divided into four groups based on a 2 × 2 factorial arrangement, with calf health status (healthy or diarrheic) and VC supplementation (VC+ or VC-) to pasteurized milk (0 or 2 g/d; 50% purity) being the main experimental factors. Calves were fed equal amounts of milk until weaning (d 60). Calves continued to be monitored until they reached 74 days of age. Calves in the VC+ group were heavier at weaning (74.3 vs. 72.2 kg; P = 0.04) compared to those calves that did not receive VC. Blood total antioxidant capacity (d 53 and 67) and superoxide dismutase activity (d 53) were greater (P < 0.01) in VC+ vs. VC- calves. Calf health status and VC supplementation interacted (P = 0.03) for blood β-hydroxybutyrate on d 53, with the lowest concentration observed in diarrheic/VC- calves. Calves in the diarrheic group had a lower total antioxidant capacity (P = 0.01) but a greater neutrophil-to-lymphocyte ratio on d 53 and 67 (P < 0.01) than calves in the healthy group. Before weaning (d 53), neutrophil-to-lymphocyte ratio was greater, but hemoglobin was lower (P = 0.02) in calves classified into the diarrheic group that did not receive supplemental VC. The number of days medicated for diarrhea treatment was lower in VC+ calves than those in VC- group (1.73 vs. 2.47 days; P = 0.05). Overall, VC supplementation in pasteurized milk improved calf growth and health. Calves that experienced elevated episodes of diarrhea within the first week of life benefited more from supplemental VC than those classified into the healthy group.
The VHI maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
The invention provides a preparation method and application of Blumea aromatica DC. ethyl acetate extract with anti-inflammatory activity, and belongs to the technical field of medicine. The Blumea aromatica DC. ethyl acetate extract with the anti-inflammatory activity and the preparation method thereof are characterized in that the extract contains effective components with the anti-inflammatory activity. The prepared Blumea aromatica DC. ethyl acetate extract has the activity of reducing animal inflammatory reactions, and has the potential value of developing anti-inflammatory products.
Participants in the control group are given information by research staff reviewing COVID-19 symptoms, home precautions, and instructions on what to do to address concerns that arise. Participants in this group complete baseline and monthly measures.